| Home : The Lancet Gastroenterology and Hepatology publishes InDex Pharmaceuticals' results of the phase IIb study with cobitolimod |
|
Oct 06
2020 |
The Lancet Gastroenterology and Hepatology publishes InDex Pharmaceuticals' results of the phase IIb study with cobitolimod |
|
STOCKHOLM, Oct. 6, 2020 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced that the results of the CONDUCT study have been published in the high-impact medical journal The Lancet Gastroenterology and Hepatology. CONDUCT was a phase IIb dose optimisation study,... |
|
|
|
| Source:https://www.prnewswire.com:443/news-releases/the-lancet-gastroenterology-and-hepatology-publishes-index-pharmaceuticals-results-of-the-phase-iib-study-with-cobitolimod-301146245.html |
| |
|
Related News
|
» Tobii divests Smartbox
» Halozyme Announces Expansion Of Collaboration And License Agreement With argenx For ENHANZE® Technology
|
